Aaron S Kesselheim MD
Hospital Medicine/Hospitalist
Assistant Professor of Medicine, Brigham and Women's Hospital
Join to View Full Profile
75 Francis StBoston, MA 02115
Phone+1 617-732-5500
Dr. Kesselheim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
Perelman School of Medicine at the University of PennsylvaniaClass of 2002
Certifications & Licensure
MA State Medical License 2004 - 2027
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2017
Publications & Presentations
PubMed
- Share of Sales Subject to Medicare Inflation Rebates and Price Increases of Top-Selling Drugs.Alexander C Egilman, Aaron S Kesselheim, Benjamin N Rome
Health Services Research. 2026-02-01 - Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic.Catherine S Hwang, Zhigang Lu, Massimiliano Russo, Heidi Zakoul, Gita A Toyserkani
Drug Safety. 2026-01-28 - Physician Perspectives on Real-World Evidence for Prescribing to Older Patients.Leah Z Rand, Junyi Wang, Steven Woloshin, Shirley V Wang, Jonathan J Darrow
Journal of Pharmacy Practice. 2026-01-18
Journal Articles
- Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated ApprovalAaron Kesselheim, MD, JAMA Internal Medicine
- Substitution of Generic Drugs and Biosimilars—ReplyAaron Kesselheim, MD, JAMA Internal Medicine
- Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic SubstitutionsAaron Kesselheim, MD, JAMA Internal Medicine
Authored Content
- Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic SubstitutionsAugust 2020
- Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic SubstitutionsAugust 2020
- Drug Prices, Rebates, and DiscountsJuly 2020
Press Mentions
Promoting Drugs to Doctors: Research Examines Potential Conflicts of InterestJanuary 26th, 2026- Legal Questions Swirl Around FDA’s New Expedited Drug Program, Including Who Should Sign offJanuary 16th, 2026
- ‘Chinese Peptides’ Are the Latest Biohacking Trend in the Tech WorldJanuary 3rd, 2026
Grant Support
- Off-Label Prescribing: Comparative Evidence, Regulation, And UtilizationAgency For Healthcare Research And Quality2009–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
